Subscribe
eNewsletter
Ready to get certified?
Free CDCES Coach App
Download
Free Med Pocket Cards
eNewsletter
Free CDCES Coach App
Free Med Pocket Cards
A new series of recommendations from JDRF/UK has set out to help ensure people with type 1 diabetes can improve access to wearable technology to manage their diabetes.
JDRF Pathway to Choice program released a report capturing the barriers, motivations, and opportunities of people with type 1 diabetes regarding medical technology.
This program in the UK aims to build awareness and access to insulin pumps, CGM’s and Flash glucose meters for persons with type 1 diabetes.
The report has three recommendations;
Karen Addington, JDRF UK’s Chief Executive states, “JDRF believes everyone who wants or would benefit from type 1 diabetes technology should gain access to it”.
As diabetes educators, nurses, doctors, dietitians, and care-givers, we support this effort in the UK for expanding access to technology that can assist people with type 1 diabetes for tighter, healthier glucose control.
Looking forward to the time that this access might be available for all persons with type 1 diabetes!
Read more by clicking here.
Written by Catherine Cullinane RN, CDCES, our resident Technology Thursday Content Writer
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
[yikes-mailchimp form=”1″]The CDC has released its 2020 annual National Diabetes Statistics Report.
This report showed that diabetes in the U.S. in on the rise. Approximately 13% of adults live with diabetes, with cases rising from 9.5% in 2002 to 13% in 2016. Many (7.3 million) are unaware that they have diabetes, as determined by A1c levels or fasting plasma glucose.
The age-adjusted data indicate that diabetes diagnoses can trend higher depending on socioeconomic status, age, and ethnicity. For example, the percent of adults with diabetes increases with age. 26.8% of those over age 65 have diabetes and new cases of type 1 and type 2 have risen in younger people.
From 2002 to 2015, incidences of type 2 diabetes among children and adolescents rose, with the largest increases of type 2 diabetes among Black non-Hispanic youth.
The report also found that cases are highest among “Native Americans and Alaskan Natives at 14.7%, Hispanic adults at 12.5%, and black adults at 11.7%. The risk increases for those from a lower socioeconomic status.
“Specifically, 13.3% of adults with less than a high school education had diagnosed diabetes vs. 9.7% of those with a high school education and 7.5% of those with more than a high school education” the report states.
The CDC explains that by analyzing the “data from this report [we] can help focus critical type 2 diabetes prevention and diabetes management efforts across the nation.”
Read the full CDC report by clicking here.
We’re updating our DiabetesEd Specialist Boot Camp throughout February and March. See the full schedule here.
In each webinar, Coach Beverly highlights the critical content of each topic area, so you can focus your study time most efficiently. She also launches multiple poll questions to helps students focus on key concepts and assess their knowledge while learning the best test-taking strategies.
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
[yikes-mailchimp form=”1″]
Our Diabetes Detective Team scans the diabetes news to discover the most relevant info that Diabetes Educators need in their daily practice. We post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
We’re updating our DiabetesEd Specialist Boot Camp throughout February and March. See the full schedule here.
In each webinar, Coach Beverly highlights the critical content of each topic area, so you can focus your study time most efficiently. She also launches multiple poll questions to helps students focus on key concepts and assess their knowledge while learning the best test-taking strategies.
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
[yikes-mailchimp form=”1″]A study released in the JAMA Pediatrics Journal revealed that approximately 18% of adolescents ages 12-18, and 24% of young adults ages 19-34 have prediabetes. These numbers have risen over the past ten years, putting young people at risk for developing Type 2 diabetes, heart disease, and other conditions down the line.
The authors of the new study says its findings:
“highlight the need for primary and secondary prevention efforts tailored to the young segment of the US population.”
The study analyzed nearly 5,800 individuals and found that prediabetes was more prevalent in males than females, both in the adolescents and young adults category. For adolescents, the study found 22.5% of males had prediabetes while 13.4% of females had prediabetes. For young adults, the ratio was 29.1% vs 18.8%.
To decrease rates of prediabetes in youth, we need to support access to healthy living resources to prevent or delay type 2 diabetes and other serious health problems.
Read more on CNN health.
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
[yikes-mailchimp form=”1″]
Tandem Diabetes Care announced the commercial USA launch of the t:slim X2 Insulin Pump with Control-IQ Technology.
The Tandem t:slim X2 with Control-IQ is a hybrid closed-loop insulin delivery system.
The Tandem t:slim X2 with Control-IQ is first and only system cleared to deliver automatic correction boluses in addition to adjusting insulin to prevent high and low blood glucose levels. The system integrates with the Dexcom G6 CGM which requires no fingersticks for calibration or diabetes treatment decisions. The goal is to increase time in range (70-180 mg/dL) for users.
Tandem President & CEO John Sheridan stated study participants and investigators have described Control-IQ Technology as “life-changing,” “easy to use,” and “a new standard of care in insulin therapy management.”
Control-IQ Technology system:
Other variables used in this hybrid closed system are:
Individual emails are being sent out to in-warranty t:slim X2 users for possible upgrades.
Technology is moving forward with improved automation and usability which is good news for people living with diabetes.
Read more here.
Written by Catherine Cullinane RN, CDCES, our resident Tech Thursday Content Writer
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
[yikes-mailchimp form=”1″]
The FDA made history last month by approving the first-ever triple combination pill for type 2 diabetes. This medication can help simplify the medication regimen for people living with type 2 diabetes.
As the director of the diabetes research unit at the University of Texas Health Science Center at San Antonio, Ralph A. DeFronzo, MD, said, “Type 2 diabetes is a complex disease that often requires the use of multiple antidiabetic medications to improve glycemic control. Having three different diabetes medications in a single tablet is an important advance in diabetes treatment.”
Known as Trijardy XR, this medication combines the SGLT2 inhibitor empagliflozin, the DPP-IV inhibitor linagliptin, and metformin extended-release. Both empagliflozin and linagliptin lower blood glucose and empagliflozin has the added benefit of reducing the risk of cardiovascular death and chronic heart failure for those living with cardiovascular disease or chronic heart failure.
Additionally, a trial that was presented at the American Diabetes Association (ADA) Scientific Sessions by Healio found that linagliptin will not increase the risk for a cardiovascular event, nor will it contribute to the progression of renal disease among people with type 2 diabetes. This trial, known as the CARMELINA trial, was conducted over six years, across a group of 6,000 people. The trial demonstrated that no “between-group differences for the incidence of nonfatal myocardial infarction, nonfatal stroke and CV death during a median of 6 years.”
There is no information on pricing as of yet. Read more about Trijardy here.
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
[yikes-mailchimp form=”1″]
Our February Newsletter celebrates the future of diabetes care and education. As we settle into the year with a new title, amazing advances in health tech, and a person-centered approach, we are excited about what’s ahead! Our newsletter and Blog Bites are focused on filling the knowledge gaps while honoring these changes, as we move into a new era of diabetes care and education.
Sign up for our Monthly Newsletter
Every weekday our Diabetes Detective Team scans the news to discover and report on the most relevant info that Diabetes Ed Specialists need for their daily practice.
The FDA made history last month by approving the first-ever triple combination pill for type 2 diabetes. This medication can help simplify the medication regimen for people living with type 2 diabetes.
As the director of the diabetes research unit at the University of Texas Health Science Center at San Antonio, Ralph A. DeFronzo, MD, said, “Type 2 diabetes is a complex disease that often requires the use of multiple antidiabetic medications to improve glycemic control. Having three different diabetes medications in a single tablet is an important advance in diabetes treatment.”
Known as Trijardy XR, this medication combines the SGLT2 inhibitor empagliflozin, the DPP-IV inhibitor linagliptin, and metformin extended-release. Both empagliflozin and linagliptin lower blood glucose and empagliflozin has the added benefit of reducing the risk of cardiovascular death and chronic heart failure for those living with cardiovascular disease or chronic heart failure.
Additionally, a trial that was presented at the American Diabetes Association (ADA) Scientific Sessions by Healio found that linagliptin will not increase the risk for a cardiovascular event, nor will it contribute to the progression of renal disease among people with type 2 diabetes. This trial, known as the CARMELINA trial, was conducted over six years, across a group of 6,000 people. The trial demonstrated that no “between-group differences for the incidence of nonfatal myocardial infarction, nonfatal stroke and CV death during a median of 6 years.”
There is no information on pricing as of yet. Read more about Trijardy here.
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
Our Diabetes Detective Team scans the diabetes news to discover the most relevant info that Diabetes Educators need in their daily practice. We post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
We’re updating our DiabetesEd Specialist Boot Camp throughout February and March. See the full schedule here.
In each webinar, Coach Beverly highlights the critical content of each topic area, so you can focus your study time most efficiently. She also launches multiple poll questions to helps students focus on key concepts and assess their knowledge while learning the best test-taking strategies.
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
[yikes-mailchimp form=”1″]